Literature DB >> 20111061

Vitreous levels of interleukine-8 and monocyte chemoattractant protein-1 in macular oedema with branch retinal vein occlusion.

A Fonollosa1, J Garcia-Arumi, E Santos, C Macia, P Fernandez, R M Segura, M A Zapata, R Rodriguez-Infante, A Boixadera, V Martinez-Castillo.   

Abstract

PURPOSE: To investigate whether interleukine-8 (IL-8) and monocyte chemoattractant protein-1 (MCP-1) are related with macular oedema in patients with branch retinal vein occlusions (BRVOs).
DESIGN: Retrospective case-control study. PARTICIPANTS: Nineteen patients who had macular oedema due to BRVO and nine patients with non-ischaemic ocular diseases (control group).
METHODS: Macular oedema was examined by optical coherence tomography. Both venous blood and vitreous samples were obtained at the time of vitreoretinal surgery. IL-8 and MCP-1 levels in vitreous fluid and plasma were determined with enzyme-linked immunosorbent assay kits. Variables were compared with the Mann-Whitney U-test, Wilcoxon's signed-ranked test, and the chi2-test, when appropriate. To examine correlations, Spearman's rank-order correlation coefficients were calculated. Statistical significance was set at P<0.05.
RESULTS: The vitreous fluid levels of IL-8 (median: 63.5 pg/ml) and MCP-1 (median: 1522.4 pg/ml) were significantly higher in the patients with BRVO than in the control group (median: 5.1 and 746.5 pg/ml respectively; P<0.001 and <0.001 respectively). Vitreous IL-8 and MCP-1 were significantly correlated in patients with BRVO (P=0.009).
CONCLUSIONS: Both IL-8 and MCP-1 were elevated in the vitreous fluid of patients with BRVO and macular oedema. Both chemokines may contribute to the pathogenesis of macular oedema in patients with BRVO.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20111061     DOI: 10.1038/eye.2009.340

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  8 in total

1.  Angiogenic Factors and Cytokines in Diabetic Retinopathy.

Authors:  Steven F Abcouwer
Journal:  J Clin Cell Immunol       Date:  2013

2.  Short-term efficacy of intravitreal triamcinolone acetonide for macular edema secondary to retinal vein occlusion that is refractory to intravitreal bevacizumab.

Authors:  Seul Gi Yoo; Jae Hui Kim; Tae Gon Lee; Chul Gu Kim; Jong Woo Kim
Journal:  Indian J Ophthalmol       Date:  2015-01       Impact factor: 1.848

3.  Possible involvement of NETosis in inflammatory processes in the eye: Evidence from a small cohort of patients.

Authors:  Tilda Barliya; Rima Dardik; Yael Nisgav; Mor Dachbash; Dan Gaton; Gili Kenet; Rita Ehrlich; Dov Weinberger; Tami Livnat
Journal:  Mol Vis       Date:  2017-12-13       Impact factor: 2.367

4.  Natural Short-term Course of Recurrent Macular Edema Following Intravitreal Bevacizumab Therapy in Branch Retinal Vein Occlusion.

Authors:  Su Jin Yoo; Jae Hui Kim; Tae Gon Lee; Jong Woo Kim; Sung Won Cho; Jung Il Han
Journal:  Korean J Ophthalmol       Date:  2017-03-21

5.  Dexamethasone Intravitreal Implant Rescue Treatment for Bevacizumab Refractory Macular Edema Secondary to Branch Retinal Vein Occlusion.

Authors:  Kyou Ho Lee; Eui Chun Kang; Hyoung Jun Koh
Journal:  Korean J Ophthalmol       Date:  2017-03-21

6.  Comprehensive analysis of vitreous chemokines involved in ischemic retinal vein occlusion.

Authors:  Yunkao Zeng; Dan Cao; Honghua Yu; Xuenan Zhuang; Dawei Yang; Yunyan Hu; Miao He; Liang Zhang
Journal:  Mol Vis       Date:  2019-11-15       Impact factor: 2.367

Review 7.  A Review of Intraocular Biomolecules in Retinal Vein Occlusion: Toward Potential Biomarkers for Companion Diagnostics.

Authors:  Bingjie Wang; Xiao Zhang; Huan Chen; Adrian Koh; Chan Zhao; Youxin Chen
Journal:  Front Pharmacol       Date:  2022-04-26       Impact factor: 5.988

8.  Efficacy of single-dose intravitreal dexamethasone implantation for retinal vein occlusion patients with refractory macular edema: A systematic review and meta-analysis.

Authors:  Qiongzhen Yuan; Yunxia Gao; Yilin Liu; Hanyue Xu; Tong Wang; Ming Zhang
Journal:  Front Pharmacol       Date:  2022-09-28       Impact factor: 5.988

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.